Kasem S. Akhras - Concepedia

Author

Kasem S. Akhras

Johnson & Johnson (United States)

Also Known As

K Akhras, K. Akhras, K. S. Akhras, K.S. Akhras, Kasem Akhras, Kasem S Akhras, Kasem S. Akhras

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)Takeda (United States)University of Illinois Chicago Rode Kruis-Vlaanderen Ninewells Hospital

About

Kasem S. Akhras is an author at Johnson & Johnson (United States) specializing in medicine, public health, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	275
2	Public Health	4	4	109
3	Global Health	2	2	35
4	Social Sciences	1	1	34
5	Epidemiology	1	1	47

Kasem S. Akhras

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Long-term mortality and medical care charges in patients with severe sepsis Derek Weycker, Kasem S. Akhras, John Edelsberg, Critical Care Medicine	2003	249
Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients Charis Marwick, J Broomhall, Colin McCowan, Journal of Antimicrobial Chemotherapy	2010	105
Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective D. Nicholl, Kasem S. Akhras, Joris Diels, Current Medical Research and Opinion	2010	87
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries J. Peuskens, J.M. Olivares, Ján Pečeňák, Current Medical Research and Opinion	2009	62
Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry J.M. Olivares, J. Peuskens, Ján Pečeňák, Current Medical Research and Opinion	2009	61
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout Eswar Krishnan, Kasem S. Akhras, Hari M. Sharma, QJM	2013	60
Comparison of the HUI3 with the SF-36 Preference Based SF-6D in a Clinical Trial Setting Hind T. Hatoum, John Brazier, Kasem S. Akhras Value in Health Clinical Trial SettingClinical TrialsRehabilitationSf-36 PreferenceMedicine	2004	58
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort Jasvinder A. Singh, Kasem S. Akhras, Aki Shiozawa Arthritis Research & Therapy Comparative EffectivenessUrologyFebuxostat Versus AllopurinolChronic Kidney DiseaseGouty Arthritis	2015	58
Outcomes and management costs in patients hospitalized for skin and skin-structure infections Kamal M.F. Itani, Sanjay Merchant, Swu‐Jane Lin, American Journal of Infection Control Clinical ManagementHealthcare-associated InfectionPatient SafetyHospital EpidemiologyOutcomes Research	2010	50
The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study Hind T. Hatoum, Kasem S. Akhras, Swu‐Jane Lin Diagnostic Microbiology and Infectious Disease Health EconomicsClinical Infectious DiseaseHealthcare-associated InfectionClinical EpidemiologySkin Structure Infections	2009	47

Page 1